Overview ARX517 in Subjects With Advanced Solid Tumor Status: Recruiting Trial end date: 2024-08-01 Target enrollment: Participant gender: Summary A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 in Subjects with Advanced Solid Tumor with known PSMA Who Failed Prior Standard Therapies Phase: Phase 1 Details Lead Sponsor: Ambrx, Inc.